38 research outputs found
Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol
Introduction Gabapentin is currently used ‘off-label’ in
children and adolescents with chronic neuropathic pain,
and reliable evidence of its effects and optimal dosing are
lacking.
Objectives The GABA-1 trial aims to compare the efficacy
and safety of gabapentin liquid formulation relative to
tramadol and to explore the pharmacokinetics of both
drugs in the treatment of chronic, neuropathic or mixed
pain in the paediatric population.
Methods and analysis The trial is a multicentre, doubleblind, double-dummy, randomised, active-controlled,
non-inferiority trial. Participants aged from 3 months to
<18 years of age with moderate to severe (≥4/10 in ageappropriate pain scales) chronic neuropathic or mixed
pain will be recruited in 14 clinical sites in eight European
countries. A total of 94 subjects will be randomised to
receive gabapentin and tramadol placebo or tramadol and
gabapentin placebo throughout 16–19 weeks (including
3 weeks of titration [optimisation period], 12 weeks of
treatment at a stable dose [maintenance period] and 1–4
weeks of tapering [discontinuation period]). The primary
objective is to assess the efficacy of gabapentin relative t
Diagnosis and Treatment of Chronic Neuropathic and Mixed Pain in Children and Adolescents: Results of a Survey Study amongst Practitioners
Validated diagnostic tools to diagnose chronic neuropathic and mixed pain in children are missing. Therapeutic options are often derived from therapeutics for adults. To investigate the international practice amongst practitioners for the diagnosis and treatment of chronic, neuropathic pain in children and adolescents, we performed a survey study among members of learned societies or groups whose members are known to treat pediatric pain. The survey included questions concerning practitioners and practice characteristics, assessment and diagnosis, treatment and medication. We analyzed 117 returned questionnaires, of which 41 (35%) were fully completed and 76 (65%) were partially completed. Most respondents based the diagnosis of neuropathic pain on physical examination (68 (58.1%)), patient history (67 (57.3%)), and underlying disease (59 (50.4%)) combined. Gabapentin, amitriptyline, and pregabalin were the first-choice treatments for moderate neuropathic pain. Tramadol, ibuprofen, amitriptyline, and paracetamol were the first-choice treatments for moderate mixed pain. Consensus on the diagnostic process of neuropathic pain in children and adolescents is lacking. Drug treatment varies widely for moderate, severe neuropathic, and mixed pain. Hence, diagnostic tools and therapy need to be harmonized and validated for use in children
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Huntington's disease (HD) is a fatal inherited neurodegenerative disorder characterized by personality changes, motor impairment, and subcortical dementia. HD is one of a number of diseases caused by expression of an expanded polyglutamine repeat. We have developed several lines of mice that are transgenic for exon 1 of the HD gene containing an expanded CAG sequence. These mice exhibit a defined neurological phenotype along with neuronal changes that are pathognomonic for the disease. We have previously observed the appearance of neuronal intranuclear inclusions, but did not find evidence for neurodegeneration. In this study, we report that all lines of these mice develop a late onset neurodegeneration within the anterior cingulate cortex, dorsal striatum, and of the Purkinje neurons of the cerebellum. Dying neurons characteristically exhibit neuronal intranuclear inclusions, condensation of both the cytoplasm and nucleus, and ruffling of the plasma membrane while maintaining ultrastructural preservation of cellular organelles. These cells do not develop blebbing of the nucleus or cytoplasm, apoptotic bodies, or fragmentation of DNA. Neuronal death occurs over a period of weeks not hours. We also find degenerating cells of similar appearance within these same regions in brains of patients who had died with HD. We therefore suggest that the mechanism of neuronal cell death in both HD and a transgenic mouse model of HD is neither by apoptosis nor by necrosis
Roles of Clinical Research Networks in Pediatric Drug Development
The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the "big picture." An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development
Multidisciplinary care in haemoglobinopathies
While most complications are related to haemoglobinopathies and their treatment, it is also possible to observe substantial differences in comorbidities’ onset and seriousness which depend also to the different HPs genotypes. These differences should be carefully considered when health authorities set up and manage adequate care systems and treatments plans. We describe services organisation in Italy including the availability of multispecialty care and tools, in the HPs units participating to the HTA-THAL Multiregional Registry, with the aim to derive the impact of the services and multispecialty care availability on the management of the disease and on the patients wellbeing. The high dispersion and heterogeneity of services demonstrated, exposes the Italian system to a high risk of: a) inappropriate use of economical and medical resources, b) limited access to multidisciplinary care of some patients with apparent inequality among different centres, and c) low patients satisfaction with the services provided. The identification of a ‘standard for HPs services’ is necessary not only at national but also at interventional level in order to implement collaborative research and the identification and networking of reference’ centres worldwide. Following the big efforts provided in the last years here there is a new challenging mission for the TIF
Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice
In a study investigating the biodiversity of endophytic nitrogen-fixing bacteria in Brazilian sugarcane plants, 31 isolates were obtained from roots, stems and leaves. Nitrogen fixation capability was determined by the acetylene reduction assay (ARA) and the presence of the nifH gene sequence was detected by dot-blot hybridization. RFLP-PCR patterns and 16S rRNA gene sequence analysis revealed the presence of 11 different bacterial genera. One strain (ICB 89T), belonging to the genus Stenotrophomonas, was further investigated using a polyphasic taxonomic approach. Strain ICB 89T is a Gram-negative, rod-shaped, non-spore-forming and nitrogen-fixing bacterium and was isolated from stems of a Brazilian sugarcane variety widely used in organic farming. 16S rRNA gene sequence analysis and DNA-DNA hybridizations revealed that strain ICB 89T is genotypically different from the closest related Stenotrophomonas species, namely S. maltophilia, S. rhizophila and S. nitritireducens. Chemotaxonomic data and biochemical characteristics allow the differentiation of strain ICB 89T from its phylogenetically nearest neighbours. Strain ICB 89T therefore represents a new species, for which the name Stenotrophomonas pavanii sp. nov. is proposed, with the type strain ICB 89T (CBMAI 564T = LMG 25348T)